PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Guan, Honggeng ^a,b   Wan, Yuqiu ^b   Lan, Jing ^b   Wang, Qin ^b   Wang, Zhangyu ^b   Li, Yecheng ^b   Zheng, Jiqing ^a   Zhang, Xueguang ^b   Wang, Zemin ^c   Shen, Yueping ^b   Xie, Fang ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; BREAST TUMOR; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; PATHOLOGY; REGULATORY B LYMPHOCYTE; REGULATORY T LYMPHOCYTE;

ADULT; B-LYMPHOCYTES, REGULATORY; B7-H1 ANTIGEN; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOPHENOTYPING; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 84992387983     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep35651     Document Type: Article

References (32)

1. Rosser, E. C., Mauri, C. Regulatory B cells in experimental mouse models of arthritis. Methods in molecular biology 1190, 183-194, doi: 10. 1007/978-1-4939-1161-5-13 (2014).
2. Blair, P. A. et al. CD19(+ )CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 32, 129-140, doi: 10. 1016/j. immuni. 2009. 11. 009 (2010).
3. Yanaba, K. et al. IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. The American journal of pathology 178, 735-743, doi: 10. 1016/j. ajpath. 2010. 10. 022 (2011).
4. Olkhanud, P. B. et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+ ) T cells to T-regulatory cells. Cancer research 71, 3505-3515, doi: 10. 1158/0008-5472. CAN-10-4316 (2011).
5. Ding, T., Yan, F., Cao, S., Ren, X. Regulatory B cell: New member of immunosuppressive cell club. Human immunology 76, 615-621, doi: 10. 1016/j. humimm. 2015. 09. 006 (2015).
6. Kalampokis, I., Yoshizaki, A., Tedder, T. F. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis research & therapy 15 Suppl 1, S1, doi: 10. 1186/ar3907 (2013).
7. Yanaba, K. et al. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28, 639-650, doi: 10. 1016/j. immuni. 2008. 03. 017 (2008).
8. de Masson, A. et al. CD24(hi)CD27(+ ) and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood 125, 1830-1839, doi: 10. 1182/blood-2014-09-599159 (2015).
9. Liu, Y. et al. Role of IL-10-producing regulatory B cells in control of cerebral malaria in Plasmodium berghei infected mice. European journal of immunology 43, 2907-2918, doi: 10. 1002/eji. 201343512 (2013).
10. Das, A. et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. Journal of immunology 189, 3925-3935, doi: 10. 4049/jimmunol. 1103139 (2012).
11. Matsushita, T., Horikawa, M., Iwata, Y., Tedder, T. F. Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. Journal of immunology 185, 2240-2252, doi: 10. 4049/jimmunol. 1001307 (2010).
12. Guan, H. et al. PD-L1 mediated the differentiation of tumor-infiltrating CD19 B lymphocytes and T cells in Invasive breast cancer. Oncoimmunology 5, e1075112, doi: 10. 1080/2162402X. 2015. 1075112 (2016).
13. Ray, A., Basu, S., Williams, C. B., Salzman, N. H., Dittel, B. N. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. Journal of immunology 188, 3188-3198, doi: 10. 4049/jimmunol. 1103354 (2012).
14. Lin, M., Wang, Z., Han, X. B Cells with Regulatory Function in Animal Models of Autoimmune and Non-Autoimmune Diseases. Open J Immunol 5, 9-17, doi: 10. 4236/oji. 2015. 51002 (2015).
15. Amarnath, S. et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Science translational medicine 3, 111ra120, doi: 10. 1126/scitranslmed. 3003130 (2011).
16. Yi, T. et al. Host APCs augment in vivo expansion of donor natural regulatory T cells via B7H1/B7. 1 in allogeneic recipients. Journal of immunology 186, 2739-2749, doi: 10. 4049/jimmunol. 1002939 (2011).
17. Yang, Z. Z. et al. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. Blood cancer journal 5, e281, doi: 10. 1038/bcj. 2015. 1 (2015).
18. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. Journal international du cancer 136, E359-E386, doi: 10. 1002/ijc. 29210 (2015).
19. Elpek, K. G., Lacelle, C., Singh, N. P., Yolcu, E. S., Shirwan, H. CD4+CD25+ T Regulatory Cells Dominate Multiple Immune Evasion Mechanisms in Early but Not Late Phases of Tumor Development in a B Cell Lymphoma Model. The Journal of Immunology 178, 6840-6848, doi: 10. 4049/jimmunol. 178. 11. 6840 (2007).
20. Martin-Orozco, N. et al. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer research 70, 9581-9590, doi: 10. 1158/0008-5472. CAN-10-1379 (2010).
21. Corthay, A. How do regulatory T cells work Scandinavian journal of immunology 70, 326-336, doi: 10. 1111/j. 1365-3083. 2009. 02308. x (2009).
22. Wakamatsu, E., Mathis, D., Benoist, C. Convergent and divergent effects of costimulatory molecules in conventional and regulatory CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America 110, 1023-1028, doi: 10. 1073/pnas. 1220688110 (2013).
23. Su, M., Huang, C. X., Dai, A. P. Immune Checkpoint Inhibitors: Therapeutic Tools for Breast Cancer. Asian Pacific journal of cancer prevention: APJCP 17, 905-910 (2016).
24. Liu, M. F., Weng, C. T., Weng, M. Y. Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus. Journal of biomedicine & biotechnology 2009, 406136, doi: 10. 1155/2009/406136 (2009).
25. Hamel, K. M. et al. B7-H1 expression on non-B and non-T cells promotes distinct effects on T-and B-cell responses in autoimmune arthritis. European journal of immunology 40, 3117-3127, doi: 10. 1002/eji. 201040690 (2010).
26. Zhang, Y. et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Critical Care 15, R70, doi: 10. 1186/cc10059 (2011).
27. Butt, A. Q., Mills, K. H. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 33, 4623-4631, doi: 10. 1038/onc. 2013. 432 (2014).
28. Salem, M. L., El-Badawy, A. Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. World journal of hepatology 7, 2449-2458, doi: 10. 4254/wjh. v7. i23. 2449 (2015).
29. Pardoll, D. M. The blockade of immune check points in cancer immunotherapy. Nature reviews. Cancer 12, 252-264, doi: 10. 1038/nrc3239 (2012).
30. Khan, A. R. et al. PD-L1hi B cells are critical regulators of humoral immunity. Nature communications 6, 5997, doi: 10. 1038/ncomms6997 (2015).
31. Kim, S. et al. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. Journal of immunotherapy 31, 446-457, doi: 10. 1097/CJI. 0b013e31816d1d6a (2008).
32. Bodogai, M. et al. Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer research 73, 2127-2138, doi: 10. 1158/0008-5472. CAN-12-4184 (2013).